Related Experiment Videos
Stimulation of nonspecific host resistance to infection induced by muramyldipeptides
Abstract:
The effect of muramyldipeptide (MDP), N-acetylmuramyl-L-alanyl-D-isoglutamine [MDP(Ala)], and its analogs on bacterial infection was studied using the experimental model of sepsis infection in mice. Injection of MDP(Ala) gave mice definitive protection against E. coli infection, but only partial protection against P. aeruginosa or K. pneumoniae infection. Several factors influencing the protective activity of MDP(Ala) on E. coli infection were studied, and it was demonstrated that the activity was induced by various routes of administration of MDP(Ala), including the oral route, and was markedly influenced by the bacterial inoculum size. It was also shown that the effective dose of MDP(Ala) was 100 micrograms per mouse for intraperitoneal, intravenous or subcutaneous injections and 1,000 microgram per mouse when administered orally. Furthermore, the optimal interval between MDP-treatment and infection was 24 hr when the treatment was carried out before infection. Clearance of bacterial cells in blood was observed after E. coli infection in mice treated with MDP(Ala). The efficacy of MDP(Ala) and two analogs, N-acetylmuramyl-L-valyl-D-isoglutamine [MDP(Val)] and N-acetylmuramyl-L-seryl-D-isoglutamine [MDP (Ser)], was evaluated for the E. coli infection; MDP(Val) was proven to be slightly less active than MDP(Ala), and MDP(Ser) to be the least effective, although MDP(Val) or MDP(Ser) was reported to have higher adjuvanticity than MDP (Ala) for the development of delayed-type hypersensitivity.
Insights
Muramyldipeptide (MDP) analogs, particularly N-acetylmuramyl-L-alanyl-D-isoglutamine [MDP(Ala)], offer protection against bacterial sepsis in mice. MDP(Ala) showed significant efficacy against E. coli, with optimal dosing and administration routes identified.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Bacterial sepsis remains a significant threat, necessitating novel therapeutic strategies.
- Muramyldipeptide (MDP) and its derivatives are known immunomodulators with potential antimicrobial effects.
Purpose of the Study:
- To evaluate the protective efficacy of muramyldipeptide (MDP) and its analogs against experimental sepsis in mice.
- To investigate factors influencing the efficacy of N-acetylmuramyl-L-alanyl-D-isoglutamine [MDP(Ala)] against E. coli infection.
Main Methods:
- Sepsis model in mice induced by bacterial infection (E. coli, P. aeruginosa, K. pneumoniae).
- Administration of MDP(Ala) and its analogs via various routes (oral, intraperitoneal, intravenous, subcutaneous).
- Determination of effective doses, optimal treatment intervals, and bacterial clearance.
Main Results:
- MDP(Ala) provided definitive protection against E. coli sepsis, with partial protection against P. aeruginosa and K. pneumoniae.
- Optimal MDP(Ala) dose was 100 µg/mouse for injection and 1000 µg/mouse orally; optimal pre-infection interval was 24 hours.
- MDP(Ala) treatment led to bacterial clearance in the blood of E. coli infected mice; MDP(Val) and MDP(Ser) showed lower efficacy.
Conclusions:
- MDP(Ala) demonstrates significant therapeutic potential against E. coli sepsis in a murine model.
- Administration route, bacterial inoculum size, and timing influence MDP(Ala)'s protective activity.
- While less effective in sepsis, MDP(Val) and MDP(Ser) exhibit higher adjuvanticity, suggesting distinct immunomodulatory roles.